Display options
Cite
Wyse JJ, McGinnis KA, Edelman EJ, et al. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS Behav. 2021;doi: 10.1007/s10461-021-03452-0.
Wyse, J. J., McGinnis, K. A., Edelman, E. J., Gordon, A. J., Manhapra, A., Fiellin, D. A., Moore, B. A., Korthuis, P. T., Kennedy, A. J., Oldfield, B. J., Gaither, J. R., Gordon, K. S., Skanderson, M., Barry, D. T., Bryant, K., Crystal, S., Justice, A. C., & Kraemer, K. L. (2021). Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS and behavior, . https://doi.org/10.1007/s10461-021-03452-0
Wyse, Jessica J, et al. "Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV." AIDS and behavior vol. (2021). doi: https://doi.org/10.1007/s10461-021-03452-0
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS Behav. 2021 Sep 08; doi: 10.1007/s10461-021-03452-0. Epub 2021 Sep 08. PMID: 34495424.
Copy Download .nbib Format: NLM
Share it on

AIDS Behav. 2021 Sep 08; doi: 10.1007/s10461-021-03452-0. Epub 2021 Sep 08.

Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV.

AIDS and behavior

Jessica J Wyse, Kathleen A McGinnis, E Jennifer Edelman, Adam J Gordon, Ajay Manhapra, David A Fiellin, Brent A Moore, P Todd Korthuis, Amy J Kennedy, Benjamin J Oldfield, Julie R Gaither, Kirsha S Gordon, Melissa Skanderson, Declan T Barry, Kendall Bryant, Stephen Crystal, Amy C Justice, Kevin L Kraemer

Affiliations

  1. VA Portland Health Care System, Portland, OR, USA. [email protected].
  2. School of Public Health, Oregon Health & Science University, Portland, OR, USA. [email protected].
  3. VA Connecticut Healthcare System, West Haven, CT, USA.
  4. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  5. Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.
  6. Informatics, Decision-Enhancement, and Analytic Sciences (IDEAS) Center, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
  7. Program for Addiction Research, Clinical Care, Knowledge and Advocacy (PARCKA), Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
  8. Integrative Pain Recovery Service, Hampton VA Medical Center, Hampton, VA, USA.
  9. APT Foundation, Pain Treatment Services, New Haven, CT, USA.
  10. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
  11. Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA.
  12. Los Angeles County Department of Health Services, Los Angeles, CA, USA.
  13. Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA.
  14. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
  15. Center for Health Services Research, Institute for Health, Rutgers University, New Brunswick, NJ, USA.
  16. Center for Research on Health Care, Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  17. VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.

PMID: 34495424 DOI: 10.1007/s10461-021-03452-0

Abstract

Although opioid agonist therapy (OAT) is associated with positive health outcomes, including improved HIV management, long-term retention in OAT remains low among patients with opioid use disorder (OUD). Using data from the Veterans Aging Cohort Study (VACS), we identify variables independently associated with OAT retention overall and by HIV status. Among 7,334 patients with OUD, 13.7% initiated OAT, and 27.8% were retained 12-months later. Likelihood of initiation and retention did not vary by HIV status. Variables associated with improved likelihood of retention included receiving buprenorphine (relative to methadone), receiving both buprenorphine and methadone at some point over the 12-month period, or diagnosis of HCV. History of homelessness was associated with a lower likelihood of retention. Predictors of retention were largely distinct between patients with HIV and patients without HIV. Findings highlight the need for clinical, systems, and research initiatives to better understand and improve OAT retention.

© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Keywords: Buprenorphine; HIV; Methadone; Opioid-related disorders; Veteran health

References

  1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Syst Rev. 2014. https://doi.org/10.1002/14651858.CD002207.pub4 . - PubMed
  2. National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: National Academies Press; 2019. - PubMed
  3. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550. - PubMed
  4. Samples H, Williams AR, Crystal S, Olfson M. Impact of long-term buprenorphine treatment on adverse health care outcomes in Medicaid: the impact of longer treatment on health care outcomes for opioid use disorder within a key population of Medicaid enrollees. Health Aff. 2020;39(5):747–55. - PubMed
  5. Edelman EJ, Chantarat T, Caffrey S, et al. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014;139:79–85. - PubMed
  6. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008;103(11):1828–36. - PubMed
  7. Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat. 2017;75:38–42. - PubMed
  8. Weiss L, Netherland J, Egan JE, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56:S68–75. - PubMed
  9. Lesko CR, Keil AP, Moore RD, Chander G, Fojo AT, Lau B. Measurement of current substance use in a cohort of HIV-infected persons in continuity HIV care, 2007–2015. Am J Epidemiol. 2018;187(9):1970–9. - PubMed
  10. Oldfield BJ, Muñoz N, McGovern MP, et al. Integration of care for HIV and opioid use disorder. AIDS. 2019;33(5):873–84. - PubMed
  11. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22. - PubMed
  12. Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287–312. - PubMed
  13. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49(9):1433–40. - PubMed
  14. Adams JW, Marshall BD, Salleh NA, Barrios R, Nolan S, Milloy MJ. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs. Drug Alcohol Depend. 2020;206:107670. - PubMed
  15. Lo-Ciganic W, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902. - PubMed
  16. Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. Am J Psychiatry. 2020;177(2):117–24. - PubMed
  17. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35. - PubMed
  18. O’Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5):e0232086. - PubMed
  19. Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26(6):572–80. - PubMed
  20. Weinstein ZM, Kim HW, Cheng DM, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65–70. - PubMed
  21. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a “virtual” cohort using the National VA Health Information System. Med Care. 2006;2006:S25–30. - PubMed
  22. Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abuse. 2018;39(2):139–44. - PubMed
  23. Kennedy AJ, McGinnis KA, Merlin JS, et al. Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. J Subst Abuse Treat. 2021;132:108509. - PubMed
  24. Substance Abuse and Mental Health Services. Federal Guidelines for Opioid Treatment Programs. HHS Publication No. (SMA) PEP15-FEDGUIDEOTP. 2015 December. https://store.samhsa.gov/sites/default/files/d7/priv/pep15-fedguideotp.pdf . Accessed August 20, 2020. - PubMed
  25. Saloner B, Daubresse M, Caleb AG. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med Care. 2017;55(7):669–76. - PubMed
  26. Oldfield BJ, McGinnis KA, Edelman EJ, et al. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. J Subst Abuse Treat. 2020;109:14–22. - PubMed
  27. Wyse JJ, Robbins JL, McGinnis KA, et al. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug Alcohol Depend. 2019;198:70–5. - PubMed
  28. McGinnis KA, Skanderson M, Edelman EJ, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: a longitudinal analysis. Drug Alcohol Depend. 2020;217:108272. - PubMed
  29. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015. - PubMed
  30. Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95:9–17. - PubMed
  31. Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abuse. 2020;2020:1–8. - PubMed
  32. Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275–82. - PubMed
  33. U.S. Department of Veterans Affairs. VHA DIRECTIVE 1304. National Human Immunodeficiency Virus Program. Washington, DC: Veterans Health Administration; 2019. Available from: https://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=3056 . - PubMed
  34. Ghose T, Gordon AJ, Metraux S, et al. The association between HIV status and homelessness among veterans in care. J Community Psychol. 2015;43(2):189–98. - PubMed
  35. Belperio PS, Chartier M, Ross DB, Alaigh P, Shulkin D. Curing hepatitis C virus infection: best practices from the US Department of Veterans Affairs. Ann Intern Med. 2017;167(7):499–504. - PubMed
  36. Hser Y-I, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79–87. - PubMed
  37. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104(7):1193–200. - PubMed
  38. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009;104(6):982–92. - PubMed
  39. Valenstein-Mah H, Hagedorn H, Kay CL, Christopher ML, Gordon AJ. Underutilization of the current clinical capacity to provide buprenorphine treatment for opioid use disorders within the Veterans Health Administration. Subst Abuse. 2018;39(3):286–8. - PubMed
  40. Chan B, Gean E, Arkhipova-Jenkins I, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2020;15(1):74–84. - PubMed

Publication Types

Grant support